Raltegravir Viatris: Withdrawal of the marketing authorisation application

The company Viatris withdrew its application for a marketing authorisation of Raltegravir Viatris for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.The company withdrew the application on 22 February 2023

Link news: https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/raltegravir-viatris